Physician profile
Michael Unger
NPI 1316995608
$35,335.13
in general payments reported to CMS, 2019-2025
19 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $1,101 · 2021: $428 · 2022: $483 · 2023: $249 · 2024: $336 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $15,386.25 | 2019-2024 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $14,236.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $3,635.62 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $389.88 | 2019-2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.88 | 2020-2024 | Caplyta |
| Abbvie INC. | $344.81 | 2021-2025 | Vraylar |
| Indivior INC. | $200.92 | 2022 | |
| Noven Therapeutics, LLC | $169.51 | 2020-2025 | Xelstrym |
| Alkermes, INC. | $141.85 | 2019-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $89.60 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $84.97 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $72.64 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $56.27 | 2019-2023 | Ingrezza |
| Almatica Pharma LLC | $48.31 | 2024-2025 | Loreev Xr |
| Allergan, INC. | $26.45 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.44 | 2025 | General - Pain Management |
| Tris Pharma INC | $20.26 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $17.45 | 2025 | Cobenfy |
| Noven Pharmaceuticals, INC. | $15.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Unger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.